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Abstract The question has been raised whether hyperpro-
lactinemia in humans is associated with an excess risk for
breastcancer.Weaimedtoassesstheriskofbreastcancerina
previously deﬁned large cohort of patients treated for idio-
pathic hyperprolactinemia or prolactinomas. Based on the
pattern of drug prescriptions we identiﬁed 11,314 subjects in
the PHARMO network with at least one dispensing of
dopamine agonists between 1996 and 2006. Of these, 1,607
subjects were considered to have dopamine agonist—treated
hyperprolactinemia based on the prescribing pattern. For the
present analysis, we included only women (n = 1,342).
Patients with breast cancer were identiﬁed by hospital dis-
charge codes. Data on breast cancer incidence in the Neth-
erlands were derived from the Dutch cancer registry.
Standardized mortality ratio (SMR) was the measure of out-
come to assess the association between hyperprolactinemia
and breast cancer. The 1,342 patients accounted for a total of
6,576 person years. Eight patients with breast cancer during
follow-up were identiﬁed. Indirect standardization with
incidence proportions from the general Dutch population
revealeda7.47expectedcases.ThecalculatedSMRforbreast
cancer risk in patients treated hyperprolactinemia was 1.07
(95% conﬁdence interval 0.50–2.03). In conclusion, there is
no clear evidence for increased breast cancer risk in female
patients treated for either idiopathic hyperprolactinemia or
prolactinomas.Theuncertaintyabouttheexactriskthatisdue
totherelativelylownumberofbreastcancercases,shouldbe
overcome by pooling results in a future meta-analysis.
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Introduction
Hyperprolactinemia that causes complaints and leads to
treatment is caused by a prolactinoma in the majority of
cases [1]. In the absence of visualization of an adenoma on
MRI, and of secondary causes such as medication, the
hyperprolactinemia is referred to as idiopathic [2]. Low
dose of a dopamine agonist is the treatment of choice in
patients with a prolactinoma or with complaints caused by
hyperprolactinemia. Dopamine agonists normalize prolac-
tin levels and decrease tumor size in the majority of cases
[3]. However, due to a delay in diagnosis, these patients
often have been exposed to increased levels of prolactin for
months to years.
Prolactin has proliferative effects on mammary epithe-
lial cells [4]. Moreover, hyperprolactinemia is associated
with oncogenesis of the mammary glands in rodents [5].
However, the issue is still unresolved, whether hyperpro-
lactinemia is associated with an excess risk for breast
cancer in female subjects [5, 6]. Nonetheless, case reports
have suggested an association between prolactinomas and
breast cancer [7, 8]. In follow-up studies higher prolactin
levels have been associated with an increased risk for
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DOI 10.1007/s11102-009-0214-ybreast cancer [9, 10]. Unfortunately, studies on prolacti-
noma patients are often underpowered to assess the risk for
breast cancer properly. Therefore, the aim of the present
analysis was to assess the risk of breast cancer in a pre-
viously deﬁned large cohort of patients treated for idio-
pathic hyperprolactinemia or prolactinomas.
Patients and methods
Study design and setting
We identiﬁed an open cohort of patients treated with dopa-
mine agonists for hyperprolactinemia using the PHARMO
network (www.pharmo.nl). This database includes the
demographic details and virtual complete medication his-
tories from community pharmacies for more than 2 million
community-dwelling residents of 25 geographic areas in the
Netherlands from 1985 to the present. These data are also
linkedtoallhospitaladmissionsofthesesubjectsthroughout
the Netherlands. All hospital discharge codes are coded
according to the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9 CM). The
ICD-9 CM codes 1,740–1,749and 2,330were usedtodeﬁne
the diagnosis of breast cancer for the present analysis. Data
on breast cancer incidence on the Netherlands were derived
from the Dutch cancer registry (www.ikcnet.nl).
According to Dutch law, there is no requirement of
informed consent if the patient data are completely anon-
ymous, cannot be traced to individual persons and patients
are not contacted for intervention purposes. Therefore, our
investigation using the PHARMO network complies with
all ethics and privacy regulations in the Netherlands.
Patients
Based on prescription patterns we identiﬁed 11,314 subjects
with at least one dispensing of dopamine agonists in the
period 1996–2006. Of these subjects, 1,607 subjects were
considered to have dopamine agonist—treated hyperpro-
lactinemia based on the prescribing pattern. Details on this
cohort have been published previously [11]. For the present
analysis on the association between breast cancer risk and
hyperprolactinemia we only included women (n = 1,342).
Analysis
Breast cancer
Hospital discharge codes were used to identify patients
with a diagnosis of breast cancer. This is a reliable marker
for breast cancer, since breast cancer is almost invariable
treated primarily by surgery, requiring hospital admission.
Prior to start of data analysis, it was decided only to count
breast cancer cases that were diagnosed after start of the
dopamine-agonist treatment for hyperprolactinemia. The
reason is that in prolactinomas the diagnosis is often
delayed, and the patients may have been exposed to ele-
vated prolactin levels years before the diagnosis [12].
Person-years
Person-years were calculated by adding the follow-up time
of all individual patients with dopamine-agonist treated
hyperprolactinemia. For the purpose of the present analy-
sis, person time was split in age bands of 5 years. For all
patients the follow-up time was started on the date of the
ﬁrst prescription of a dopamine agonist in the database.
End of follow-up time was determined by the date of the
last prescription in the database for that particular patient,
irrespective whether this was for a dopamine-agonist, or for
another reason.
Incidences in the Netherlands
For the purpose of the analysis the average incidence of the
breast cancer in The Netherlands of the calendar years
1996–2006 was taken. The incidences were stratiﬁed by
5 years of age.
Standardized mortality ratio
Standardized mortality ratio (SMR) was the measure of
outcome to assess the association between hyperprolacti-
nemia and breast cancer. In a SMR the observed number of
breast cancer cases in the cohort was compared to the
expected number of cases that would have occurred theo-
retically if the breast cancer risk in the general population
is applied to the calculated person-years from the hyper-
prolactinemia cohort.
Results
Patients and person-years
The original database consisted of 11,314 subjects with at
least one prescription of dopamine agonists with a total of
37,380 prescriptions of dopamine agonists in the period
from January 1, 1996 and December 31, 2006. A total of
1,607 patients with dopamine agonist—treated hyperpro-
lactinemia were identiﬁed [11]. For the present analysis
only women were included (n = 1,342).
Mean age of treated female patients was 36 ± 11 years.
The initial treatment was bromocriptine in 545 patients
(41%), cabergoline in 556 patients (41%) and quinagolide
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31 patients. The mean initial treatment duration was
16.5 months. In 515 patients, dopamine agonist therapy
was restarted.
Breast cancer
Based on hospital discharge codes, eight patients with
breast cancer during follow-up were identiﬁed. The youn-
gest patient was 38 years at the time of diagnosis, the
oldest was 61 years. Breast cancer was diagnosed from
11 months to 8 years and 5 months after the ﬁrst pre-
scription of a dopamine agonist.
Standardized mortality ratio
The 1,342 patients accounted for a total 6,576 person years
of follow up. Indirect standardization with incidence pro-
portions from the general Dutch population revealed a total
number of expected cases of 7.47. The calculated SMR for
breast cancer risk in patients treated hyperprolactinemia
was 1.07 (95% conﬁdence interval 0.50–2.03).
Discussion
The present analysis was conducted to estimate the risk of
breast cancer in a large cohort of patients treated for
hyperprolactinemia. Compared to the general Dutch pop-
ulation, there was no clearly increased risk (SMR 1.07).
However, because the number of patients with breast
cancer was rather low, the conﬁdence intervals of this
analysis are rather broad, thereby prohibiting a deﬁnitive
conclusion on the possible association between breast
cancer risk and hyperprolactinemia.
This study has limitations. Although the cohort of
included patients of dopamine agonist-treated hyperpro-
lactinemia is relatively large, the number of breast cancer
cases during follow-up was rather small (n = 8). The low
number of breast cancer cases is due to two facts: ﬁrstly, a
relatively short follow-up period of about 5 years and
secondly the relatively young age of patients at diagnosis.
Because the conﬁdence interval for a SMR is based on the
number of events, i.e. the number of patients who develop
breast cancer, and not on the number of patients in the
cohort, the conﬁdence intervals were wide. This limitation
can only be overcome by including even larger cohorts, or
by pooling existing data in a meta-analysis. Secondly, the
diagnosis of hyperprolactinemia was based on prescriptions
of dopamine agonists in a large pharmaco-epidemiological
database. This has been shown to be a reliable approach for
the identiﬁcation of patients idiopathic hyperprolactinemia
or prolactinomas [11]. Another limitation of the present
analysis is the fact that no prolactin values of individual
patients were known. Therefore, analysis according to
initial prolactin levels was not possible. Moreover, strati-
ﬁed analysis according to disease duration was not possi-
ble. Selection bias is a potential other limitation. The
diagnoses in our cohort were based on hospital discharge
codes, whereas the diagnoses from the Dutch cancer reg-
istry were based on either hospital discharge codes or on
tissue diagnosis. Since breast cancer is almost invariable
treated primarily by surgery, requiring hospital admission,
the selection bias will not be large.
Exposure to overproduction of pituitary hormones can
lead to an increased risk for cancer, as has been shown in
acromegaly [13].The suggested association between breast
cancer and elevated levels of prolactin was based on case
reports [7, 8], basic research [5] and epidemiological
studies [9, 10]. However, thus far, no association between
breast cancer risk and idiopathic hyperprolactinemia/pro-
lactinoma has been shown. This is mainly due to the fact
that the majority of presented series with prolactinomas are
underpowered to detect a possible association [13].
In the present analysis there was no clear association
between breast cancer and patients treated for hyperpro-
lactinemia. The inclusion of both prolactinomas and idio-
pathic hyperprolactinemia enhances the generalizability of
the results [14]. However, the ultimate verdict on the
association between prolactinomas and breast cancer
would require a larger cohort. Despite this limitation our
study is incompatible with a large breast cancer risk, i.e. a
relative risk[2. Several considerations have to be taken
into account when interpreting this result. Firstly, the
association was assessed in female patients, whereas some
case reports described a male patient with breast cancer [7,
15]. In female patients the levels of prolactin at presenta-
tion are clearly lower than in men, mainly because men
present more often with larger adenomas [16]. In our
database, breast cancer was not diagnosed in any of the
male patients. Secondly, all patients in the cohort included
for the present analysis were treated with dopamine ago-
nists. This treatment is very effective in normalizing pro-
lactin levels [17]. This means that in the follow-up period
after start of the medication prolactin levels can be
assumed to be normalized in the vast majority of cases.
However, in most patients the diagnosis is often delayed
and the disease can therefore be accompanied by long-term
overexposure to prolactin [12]. Thirdly, estrogens are
known to increase the risk of breast cancer [4]. Elevation of
prolactin leads to suppression of the estrogen-production
by inhibition of the release of luteinizing hormone and the
follicle stimulating hormone [3]. The net effect of prolactin
on breast cancer risk is therefore also dependent on the
degree of suppression of the estrogen production. Theo-
retically, an increased risk for breast cancer due to
Pituitary (2010) 13:195–198 197
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decreased production of estrogens.
In conclusion, this study showed no clear evidence for
increased breast cancer risk in female patients treated for
ether idiopathic hyperprolactinemia or prolactinomas. The
uncertainty about the exact risk that is due to the relatively
low number of breast cancer cases, should be overcome by
pooling results in a future meta-analysis.
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